INFORM - surgery for hip infection project

Conditions

Topic: Surgery

Ashley Blom, Andrew D Beswick, Amanda Burston, Fran Carroll, Kirsty Garfield et al. (18 authors)

Programme Grants for Applied Research2022-11-0119 citations

Clinical and cost effectiveness of single stage compared with two stage revision for hip prosthetic joint infection (INFORM): pragmatic, parallel group, open label, randomised controlled trial

Ashley Blom, Erik Lenguerrand, Simon Strange, Sian Noble, Andrew D Beswick et al. (18 authors)

BMJ2022-10-3166 citations

10.1136/bmj-2022-071281

One-stage or two-stage revision surgery for prosthetic hip joint infection--the INFORM trial: a study protocol for a randomised controlled trial.

Strange S, Whitehouse MR, Beswick AD, Board T, Burston A, Burston B, Carroll FE, Dieppe P, Garfield K, Gooberman-Hill R, Jones S, Kunutsor S, Lane A, Lenguerrand E, MacGowan A, Moore A, Noble S, Simon J, Stockley I, Taylor AH, Toms A, Webb J, Whittaker JP, Wilson M, Wylde V, Blom AW.

2016-02-1753 citations

10.1186/s13063-016-1213-8

Interventions

Revision hip surgery 1-stage or 2-stage revision for infected prosthetic hip joint

Follow Up Length: 18 month(s)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age 18 or above 2. A clinical diagnosis of prosthetic hip joint infection 3. Require revision surgery (either 1-stage or 2-stage) to treat prosthetic hip joint infection, in the opinion of the treating consultant orthopaedic surgeon Target Gender: Male & Female ; Lower Age Limit 18 years

Exclusion criteria

Exclusion criteria: 1. Unable or unwilling to undergo either 1-stage or 2-stage revision surgery 2. Lack capacity to give written informed consent

Design outcomes

Primary

Measure	Time frame
Patient-reported hip pain, stiffness, function; Timepoint(s): WOMAC at 18 months post-randomisation	—

Secondary

Measure	Time frame
1. Quality of life, measured using Euroquol EQ-5D-5L and HOOS 2. All hip-related complications (including continuing and reinfection) recorded throughout study period 3. Post-op pain, measured using the Brief Pain Inventory 4. Patient-reported hip function, measured using the Oxford Hip Score 5. Objective measure of hip function, measured using the 20 metre timed walk test 6. Depression and anxiety, measured using the Hospital Anxiety and Depression Score 7. Cost-effectiveness of interventions, measured using health resource use	—

Measure

Time frame

1. Quality of life, measured using Euroquol EQ-5D-5L and HOOS 2. All hip-related complications (including continuing and reinfection) recorded throughout study period 3. Post-op pain, measured using the Brief Pain Inventory 4. Patient-reported hip function, measured using the Oxford Hip Score 5. Objective measure of hip function, measured using the 20 metre timed walk test 6. Depression and anxiety, measured using the Hospital Anxiety and Depression Score 7. Cost-effectiveness of interventions, measured using health resource use

—

Countries

England, Sweden, United Kingdom

Outcome results

None listed